Rectal Cancer
Conditions
Brief summary
Colorectal cancer is common with an annual prevalence of 6000. The majority can be cured and the five year survival rate is over 60%. In december 2019 reports came in about SARS-Cov-2, which later was named Covid-19. The World Health Organization classified it as a pandemic in March 2020. In Sweden the number of patients with Covid-19 increased mainly in the urban areas in March 2020. Care for patients with other diseases were affected and local changes from guidelines were adopted. In some regions and countries the indications for adjuvant and neoadjuvant treatment for colorectal cancer were somewhat changed. The number of patients diagnosed with colorectal cancer also decreased, as well as other types of cancer. The true effect on outcome with a delayed diagnosis remains unknown. The aim of this study is to evaluate the effects of the Covid-19 pandemic on the diagnosis, treatment and survival of patients with colorectal cancer.
Interventions
OTHERDiagnosed during or not during the pandemic
We will create a group of patients that are diagnosed before and after the pandemic and one group diagnosed during the pandemic
Sponsors
Sahlgrenska University Hospital
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Rectal cancer diagnosis 2019-2022
Exclusion criteria
* No rectal cancer diagnosis 2019-2022
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Yearly incidence of rectal cancer | 2019-2022 | The number of patients diagnosed yearly 2019, 2020, 2021 and 2022 |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Symptoms at diagnosis | 6 months prior diagnosis | Symptoms at diagnosis as reported by patients |
| Patient's delay | 12 months prior diagnosis | Delay from symptoms until doctors appointment |
| Doctor's delay | 12 months prior diagnosis | Delay from doctor's appointment until diagnosis |
| Treatment changes | Diagnosis and 12 months following | Any changes from the treatment plan due to covid-19 |
Countries
Sweden
Contacts
Primary ContactEva Angenete, MD. PhD
Backup ContactAnette Wedin, RN
Outcome results
None listed